Skip to content
akaturk Academic measurement

Academician

ELİF MERVE HELVACI

ARAŞTIRMA GÖREVLİSİ

ONDOKUZ MAYIS ÜNİVERSİTESİ LİSANSÜSTÜ EĞİTİM ENSTİTÜSÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Sinirbilimi

A quick look at recorded outputs — details below.

  • Articles 6
  • Projects 0
  • Books 1
  • Proceedings 24
  • Patents 0
  • Artistic 0
Scopus (SJR) Q1 4 Q2 0 Q3 1 Q4 0
WoS (JCR) Q1 0 Q2 4 Q3 0 Q4 1
TR Index 2 articles

Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.

Top 1% articles 0
Top 10% articles 1
Avg percentile 66.6%
Top 1% share 0.0%
Top 10% share 20.0%

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

Index filters

6 publications total

Scopus (SJR)
Q1 4 Q2 0 Q3 1 Q4 0
WoS (JCR)
Q1 0 Q2 4 Q3 0 Q4 1
TR Index

Article list

  1. 2026 The Effect of Overweight and Obesity on Contralateral Suppression in Patients with Multiple Sclerosis* Balkan ORL-HNS DOI 10.5152/bohns.2026.25108 YÖKSİS TR Index OpenAlex 18.2%
  2. 2025 Corrigendum to “The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis” [Multiple Sclerosis and Related Disorders 83 (2024) 105391] Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2025.106307 YÖKSİS SJR Q1 JCR Q2
  3. 2024 The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2023.105391 YÖKSİS SJR Q1 JCR Q2 OpenAlex 87.5%
  4. 2024 The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2023.105391 YÖKSİS SJR Q1 JCR Q2 OpenAlex 87.5%
  5. 2023 Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment Turk Noropsikiyatri Dernegi DOI 10.29399/npa.28081 YÖKSİS TR Index SJR Q3 JCR Q4 OpenAlex 43.9%
  6. 2023 Is Mediterranean diet associated with multiple sclerosis related symptoms and fatigue severity? Nutritional Neuroscience DOI 10.1080/1028415X.2022.2034241 YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 95.6%
  7. 2023 Two-year Assessment of the Efficacy and Safety of Ocrelizumab in Switching Patients from Other Disease Modifying Therapies Journal of Multiple Sclerosis DOI 10.35248/2376-0389.22.9.12.475 YÖKSİS

Back to academicians